Cardiac Excitation-Contraction Coupling Explained

The Frank-Starling law states that increased venous return causes greater cardiac contractility. Mechanistically, sarcomere stretch exposes more calcium-binding sites on troponin C, allowing more calcium binding during excitation-contraction coupling. This mobilizes tropomyosin and releases myosin-binding sites on actin, increasing cross-bridge formation and strengthening contraction.

The Frank-Starling mechanism is a physiological adaptation where increased ventricular filling (preload) leads to increased cardiac contractility and stroke volume, maintaining constant end-systolic volume while elevating both stroke volume and systolic blood pressure; this occurs because greater muscle fiber stretch opens mechanically coupled calcium channels and improves myosin-actin binding site positioning, enhancing contraction force.

The Frank-Starling Law states that the force of cardiac muscle contraction increases with greater preload (the volume of blood stretching the heart wall before contraction), because optimal stretching of cardiac muscle fibers exposes more active sites on myosin filaments, allowing more cross-bridges to form and generate greater contraction force; however, this relationship only holds up to a physiological limit, beyond which excessive stretching reduces contraction force, as seen in congestive heart failure.

The Frank-Starling law states that the force of ventricular contraction during systole is directly proportional to the degree of ventricular stretching during diastole. This mechanism, also called heterometric regulation, occurs because: (1) Venoous return stretches the myocardium; (2) When myocardium is stretched moderately (130-140 ml end-diastolic volume), force of contraction increases; (3) When stretched more (up to 180 ml), more cross-bridges form between actin and myosin filaments, increasing contraction force; (4) If venous return is insufficient or excessive (around 80 ml), a-systole occurs and the heart cannot compensate.

The Frank-Starling mechanism is the heart's intrinsic ability to adapt to venous return variations. When preload increases (greater end-diastolic volume), cardiac muscle fibers stretch and lengthen. As fiber length increases, greater force is developed during contraction, increasing stroke volume. This self-regulating mechanism allows the heart to match output to input without external neural control. The mechanism operates because cardiac muscle fibers typically start contraction at suboptimal lengths, and increased filling stretches them toward optimal length for maximum tension generation.

Digitalis inhibits the sodium-potassium pump, reducing extracellular sodium and decreasing sodium-calcium exchange. This prevents calcium from leaving the cell, increasing intracellular calcium and enhancing cardiac contractility—useful in heart failure treatment. Beta-blockers reduce contractility by blocking beta-1 receptors, decreasing cAMP and calcium release. Calcium channel blockers prevent calcium influx into cardiac cells. These drugs modulate cardiac function in conditions like heart failure and hypertension, balancing contractility with reduced workload.

Contractility refers to the intrinsic strength of cardiac muscle contraction independent of preload. The sympathetic nervous system increases contractility through beta-1 adrenergic receptor activation, enhancing intracellular calcium levels for cross-bridge cycling. Thyroid hormones T3/T4 increase contractility by upregulating beta-1 receptor expression. Positive inotropic agents include digitalis (sodium-potassium ATPase inhibitor), dopamine, dobutamine, and isoprenaline. Negative inotropic agents include beta-blockers and calcium channel blockers. Ion effects: hypercalcemia increases contractility, while hyperkalemia, hypernatremia, and acidosis all decrease contractility. These molecular mechanisms explain how cardiac function can be pharmacologically modulated in clinical settings.

This extensive section covers drug strategies for increasing and decreasing heart contractility. To increase contractility: stimulate sympathetic system via beta-1 receptors (adrenaline, dobutamine), inhibit parasympathetic system via muscarinic receptors (atropine), or inhibit sodium-potassium ATPase (digoxin). To decrease contractility: inhibit sympathetic system via beta-1 receptors (beta-blockers), stimulate parasympathetic system via muscarinic receptors, or inhibit calcium channels. The instructor details beta-1 agonists: adrenaline stimulates multiple receptors (beta-1, alpha-1, beta-2), dopamine has dose-dependent effects (renal vasodilation at low doses, beta-1 stimulation at moderate doses, alpha-1 vasoconstriction at high doses), and dobutamine is highly selective for beta-1 receptors. Beta-blockers decrease heart rate and contractility by blocking beta-1 receptors, used for tachycardia, hypertension, and heart failure. Generations differ in selectivity: first-generation blocks both beta-1 and beta-2, second-generation is selective for beta-1, third-generation blocks both plus alpha-1. Non-selective blockers are contraindicated in asthma. Calcium channel blockers slow calcium flow through calcium channels in the SA node and blood vessels, decreasing heart rate and causing vasodilation. For heart failure, dobutamine is preferred due to beta-1 selectivity. For tachycardia in asthma patients, selective beta-1 blockers are preferred to avoid bronchoconstriction.

This section covers drugs that directly modulate cardiac contractility and vascular resistance. Digitalis (digoxin) blocks sodium-potassium ATPase, raising intracellular sodium and preventing calcium extrusion through the sodium-calcium exchanger, producing positive inotropy, while also acting as a vagomimetic agent. Vasodilator drugs are classified as venodilators (nitrates, decreasing preload), arteriolar dilators (hydralazine, minoxidil, decreasing afterload), and mixed-effect drugs (nitroprusside). Calcium channel blockers are divided into dihydropyridines (pure arteriolar dilators) and non-dihydropyridines (verapamil, diltiazem with negative inotropic and AV nodal blocking effects). Clinical uses include anti-anginal therapy, hypertension management, and rate control for supraventricular arrhythmias.

Beta-adrenergic blockers work by blocking beta-1 receptors on the heart, reducing heart rate and contractility to decrease oxygen demand. They also block calcium influx into smooth muscle cells, preventing contraction. This reduces the risk of heart attack by preventing tachycardia. Common side effects include bradycardia, hypotension, bronchospasm, depression, and sexual dysfunction. Calcium channel blockers block calcium ion channels in cardiac and smooth muscle cells, reducing contractility and causing vasodilation. This reduces both preload and afterload, improving coronary perfusion. These drugs are used for preventive treatment to reduce future heart attack risk.

Heart failure affects many people in the United States with high mortality primarily due to contractile dysfunction. The genesis is multifactorial, but cellular calcium alterations and calcium regulation may represent the final common pathway. Excitation-contraction coupling involves proteins including the sodium-calcium exchanger, calcium channels, and sarcoplasmic reticulum calcium ATPase. In normal conditions, calcium signaling produces uniform elevation with a one-to-one relationship between calcium release and contraction. In heart failure, calcium release becomes asynchronous, occurring at different phases of excitation, disrupting the normal relationship. This asynchronous calcium release can produce delayed afterdepolarizations (DADs), which can be induced by repetitive stimulation. Ventricular tachycardia in heart failure is initiated by a focal mechanism due to trigger activity, primarily from DADs. CPVT is a rare inherited arrhythmia characterized by adrenergic-mediated exercise-induced bidirectional polymorphic ventricular tachycardia, leading to syncope or sudden cardiac death in the absence of structural heart disease. Approximately 30% of patients die before age 40.

Excitation-contraction coupling links electrical excitation to mechanical contraction via calcium as the primary mediator. Electrical excitation triggers L-type calcium channel activation, which induces massive calcium release from the sarcoplasmic reticulum through calcium-induced calcium release. This calcium binds to contractile filaments to initiate contraction. During diastole, calcium is pumped back into the SR or removed by the sodium-calcium exchanger. Spontaneous ryanodine receptor openings during diastole produce calcium sparks that can accumulate into waves. The sodium-calcium exchanger generates delayed afterdepolarizations (DADs) during calcium removal, which can trigger new action potentials if sufficiently large. This reverse excitation-contraction coupling mechanism contributes to both atrial and ventricular arrhythmias.

Dilated cardiomyopathy features distended, stretched-out heart chambers with thin muscle walls, similar to a sagging sock. This stretching causes valve regurgitation (leaky valves) and weakens contraction. The result is systolic heart failure where blood backs up into the lungs and body. The body compensates by increasing heart rate through the sympathetic nervous system and activating the renin-angiotensin-aldosterone system (RAAS), causing kidneys to retain fluid and raise blood pressure. However, these compensatory mechanisms eventually fail, leading to progressive heart failure.

Dilated cardiomyopathy is the most common type of cardiomyopathy, characterized by ventricular dilation and impaired contraction leading to reduced ejection fraction; it results from various causes including genetics, viral infections (particularly Coxsackie B virus), substance abuse, coronary artery disease, and valvular diseases, presenting clinically with heart failure symptoms such as dyspnea, orthopnea, and the presence of an S3 gallop, and is managed through standard heart failure therapy including fluid restriction, diuretics, ACE inhibitors, beta blockers, spironolactone, and potentially implantable cardioverter defibrillators or heart transplantation.

Dilated cardiomyopathy is a primary disease of the heart muscle characterized by systolic dysfunction, where the heart muscle weakens and cannot contract effectively, leading to decreased ejection fraction (less than 50-75% of blood being pumped out per beat); the heart compensates by dilating its chambers, which eventually leads to heart failure symptoms such as chest pain, fainting, and swelling (edema) from blood backing up; causes include genetic factors, viral myocarditis, alcohol toxicity, pregnancy, and idiopathic factors, though it is not caused by ischemic heart disease, valvular heart disease, or hypertension; diagnosis involves history/physical exam, BNP blood test, EKG (which is usually abnormal but non-specific), chest X-ray showing cardiomegaly, and echocardiogram (the best test) to visualize chamber dilation and measure ejection fraction.